Observational analysis reveals enhanced T cell memory features in patients with solid tumors, indicating potential treatment benefits from IL-12 therapy.
Supplementary Figure 5. Differences in TCF1+ T cell subsets by response and dosing schedule.
No takes yet. Share an insight, caveat, or question.
Goswami et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: